The Guest Editors of this issue of Urologic Clinics of North America have put together a comprehensive collection of articles that provides the current knowledge on urologic cancer immunotherapy. Expert authors have contributed clinical review articles on the following topics: Era of personalized vaccines for GU cancers; TCR and dendritic vaccine platforms for GU cancers; Neo-adjuvant platforms for GU cancer immunotherapy; Immune-editing in Cancer: Role of tumor microenvironment and immune-suppressive pathways in localized and aggressive disease; Clinical integration of neo-adjuvant platforms for prostate cancer immunotherapy; Immunotherapy for muscle and non-muscle invasive bladder cancer: BCG and beyond; Immunotherapy for metastatic bladder cancer; Immunotherapy options for metastatic castrate-resistant prostate cancer; Role of tissue infiltrating lymphocytes: Understanding TCR; Therapeutic platforms for IPSC-derived CAR-T; Immune-suppression in prostate cancer: Underlying causes and influence on response to immunotherapy; and Racial disparity in response to immunotherapy. Urologists will come away with the most current information they need to improve outcomes in the urologic cancer patient.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Urologic Clinics of North America - p. x 7. Preface - p. xi 8. William B. Coley: His Hypothesis, His Toxin, and the Birth of Immunotherapy - p. 413 9. Kidney Cancer: An Overview of Current Therapeutic Approaches - p. 419 10. Harnessing Natural Killer Cell Function for Genitourinary Cancers - p. 433 11. Immunotherapy for Localized Prostate Cancer: The Next Frontier? - p. 443 12. The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer - p. 457 13. Immunotherapy for Prostate Cancer: Treatments for the “Lethal” Phenotype - p. 469 14. Application of Single-Cell Sequencing to Immunotherapy - p. 475 15. Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options - p. 487 16. Biotech and Breakthroughs in Immuno-Oncology - p. 511 17. Special Article - p. 521 18. Personalized Medicine for the Infertile Male - p. 523
The Guest Editors of this issue of Urologic Clinics of North America have put together a comprehensive collection of articles that provides the current knowledge on urologic cancer immunotherapy. Expert authors have contributed clinical review articles on the following topics: Era of personalized vaccines for GU cancers; TCR and dendritic vaccine platforms for GU cancers; Neo-adjuvant platforms for GU cancer immunotherapy; Immune-editing in Cancer: Role of tumor microenvironment and immune-suppressive pathways in localized and aggressive disease; Clinical integration of neo-adjuvant platforms for prostate cancer immunotherapy; Immunotherapy for muscle and non-muscle invasive bladder cancer: BCG and beyond; Immunotherapy for metastatic bladder cancer; Immunotherapy options for metastatic castrate-resistant prostate cancer; Role of tissue infiltrating lymphocytes: Understanding TCR; Therapeutic platforms for IPSC-derived CAR-T; Immune-suppression in prostate cancer: Underlying causes and influence on response to immunotherapy; and Racial disparity in response to immunotherapy. Urologists will come away with the most current information they need to improve outcomes in the urologic cancer patient.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Urologic Clinics of North America - p. x 7. Preface - p. xi 8. William B. Coley: His Hypothesis, His Toxin, and the Birth of Immunotherapy - p. 413 9. Kidney Cancer: An Overview of Current Therapeutic Approaches - p. 419 10. Harnessing Natural Killer Cell Function for Genitourinary Cancers - p. 433 11. Immunotherapy for Localized Prostate Cancer: The Next Frontier? - p. 443 12. The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer - p. 457 13. Immunotherapy for Prostate Cancer: Treatments for the “Lethal” Phenotype - p. 469 14. Application of Single-Cell Sequencing to Immunotherapy - p. 475 15. Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options - p. 487 16. Biotech and Breakthroughs in Immuno-Oncology - p. 511 17. Special Article - p. 521 18. Personalized Medicine for the Infertile Male - p. 523
